Transforming growth factor‐β1 is a heparin‐binding protein: Identification of putative heparin‐binding regions and isolation of heparins with varying affinity for TGF‐β1
- 1 August 1992
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 152 (2) , 430-440
- https://doi.org/10.1002/jcp.1041520226
Abstract
Previous studies indicated that a major factor in heparin's ability to suppress the proliferation of vascular smooth muscle cells is an interaction with transforming growth factor‐β1 (TGF‐β1). Heparin appeared to bind directly to TGF‐β1 and to prevent the association of TGF‐β1 with α2‐macroglobulin (α2‐M). The present studies indicate that 20–70% of iodinated TGF‐β1 binds to heparin‐Sepharose and the retained fraction is eluted with ∼0.37 M NaCI. Native, unlabelled platelet TGF‐β1, however, is completely retained by heparin‐Sepharose and eluted with 0.9–1.2 M NaCI. Using synthetic peptides, the regions of TGF‐β1 that might be involved in the binding of heparin and other polyanions were examined. Sequence analysis of TGF‐β1 indicated three regions with a high concentration of basic residues. Two of these regions had the basic residues arranged in a pattern homologous to reported consensus heparin‐binding regions of other proteins. The third constituted a structurally novel pattern of basic residues. Synthetic peptides homologous to these three regions, but not to other regions of TGF‐β1, were found to bind to heparin‐Sepharose and were eluted with 0.15 M‐0.30 M NaCI. Only two of these regions were capable of blocking the binding of heparin to 125I‐TGF‐β. Immobilization of these peptides, followed by affinity purification of heparin, indicated that one peptide was capable of isolating subspecies of heparin with high and low affinity for authentic TGF‐β1. The ability of TGF‐β1 to bind to heparin or related proteoglycans under physiological conditions may be useful in understanding the biology of this pluripotent growth and metabolic signal. Conversely, a subspecies of heparin molecules with high affinity for TGF‐β1 may be a factor in some of the diverse biological actions of heparin.Keywords
This publication has 67 references indexed in Scilit:
- Fucoidan is a non-anticoagulant inhibitor of intimal hyperplasiaBiochemical and Biophysical Research Communications, 1992
- Transforming growth factor β type 1 binds to collagen IV of basement membrane matrix: Implications for developmentDevelopmental Biology, 1991
- Bifunctional effects of transforming growth factor-β (TGF-β) on endothelial cell growth correlate with phenotypes of TGF-β binding sitesExperimental Cell Research, 1990
- Purification of transforming growth factor type eJournal of Cellular Biochemistry, 1990
- Heparin increases mRNA levels of thrombospondin but not fibronectin in human vascular smooth muscle cellsBiochemical and Biophysical Research Communications, 1989
- Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half‐lifeJournal of Cellular Physiology, 1989
- Heparan sulphate with no affinity for antithrombin III and the control of haemostasisFEBS Letters, 1988
- Aging and arteriosclerosis. The increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity.The Journal of Experimental Medicine, 1988
- Preparation and binding of radioactively labeled porcine transforming growth factor type βBiochemical and Biophysical Research Communications, 1986
- Heparin-induced osteoporosisThe British Journal of Radiology, 1973